InMode (INMD) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
10 Feb, 2026Executive summary
Q4 2025 revenue rose 6% year-over-year to $103.9M, but full-year 2025 revenue declined 6% to $370.5M amid industry headwinds and softer North American demand.
Leadership changes and organizational unification in North America aim to drive results in 2026.
Product innovation and launches, including CO2 laser platforms and upcoming Pico and Morpheus/Erbium YAG devices, are central to long-term strategy.
Leading provider of minimally-invasive aesthetic and wellness solutions with a global reach, serving over 100,000 U.S. and 200,000+ global physicians.
$127.4M returned to shareholders via share repurchases in 2025.
Financial highlights
Q4 2025 revenue was $103.9M; full-year 2025 revenue was $370.5M, with non-GAAP net income of $105.5M and non-GAAP diluted EPS of $1.60.
Q4 2025 GAAP gross margin was 78%; non-GAAP gross margin was 79% for Q4 and full year.
Q4 2025 GAAP operating margin: 25%; non-GAAP: 27%. FY 2025 GAAP operating margin: 23%; non-GAAP: 26%.
Cash and equivalents at year-end were $555.3M.
Installed base includes 13,100 units in the US and 30,980 units worldwide.
Outlook and guidance
2026 revenue expected between $365M-$375M, roughly flat with 2025.
Non-GAAP gross margin guidance: 75%-77%; non-GAAP operating income: $87M-$92M; non-GAAP EPS: $1.43-$1.48.
Two new laser-based platforms to launch in 2026.
2026 is anticipated as a stabilization year, with growth initiatives expected to yield results in 2027.
Latest events from InMode
- Product innovation, high margins, and disciplined capital allocation drive growth amid macro headwinds.INMD
Jefferies Global Healthcare Conference9 Jul 2026 - Strong innovation and global expansion position the firm for recovery despite current headwinds.INMD
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20249 Jul 2026 - Revenue and margins fell as U.S. demand softened, but international growth and capital returns continued.INMD
Q1 20258 Jul 2026 - Revenue was $130.2M, margins declined, but new platforms gained traction amid headwinds.INMD
Q3 20248 Jul 2026 - Flat revenue outlook, margin pressure, and new products set the stage for future growth.INMD
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q1 2026 revenue reached $82M with 75% gross margin and ongoing share repurchases.INMD
Q1 20266 May 2026 - Growth from new products offsets margin pressure; global expansion and R&D drive future potential.INMD
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Manufacturing and logistics face disruption, but strategic buybacks and global expansion continue.INMD
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Flat top line expected in 2026, with new products and restructuring to drive future recovery.INMD
Barclays 28th Annual Global Healthcare Conference11 Mar 2026